Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy

References

• Garattini L, Padula A. Cholesterol-lowering drugs: science and marketing. J R Soc Med. 2017;110(2):57–64. doi:10.1177/0141076816681951
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Talic S, Marquina C, Ofori-Asenso R, et al. Switching, persistence and adherence to statin therapy: a retrospective cohort study using the Australian national pharmacy data. Cardiovasc Drugs Ther. 2021. doi:10.1007/s10557-021-07199-7
   PubMed Web of Science ®Google Scholar
• Lansberg P, Lee A, Lee Z-V, Subramaniam K, Setia S. Nonadherence to statins: individualized intervention strategies outside the pill box. Vasc Health Risk Manag. 2018;14:91–102. doi:10.2147/VHRM.S158641
   PubMed Web of Science ®Google Scholar
• Wu R, Rison S, Raisi-Estabragh Z, et al. Benefits from optimised antihypertensive and statin treatment in high risk people. Eur Heart J. 2021;42(Supplement_1):ehab724.2728. doi:10.1093/eurheartj/ehab724.2728
   Google Scholar
• Zhang Y, Flory JH, Bao Y. Chronic medication nonadherence and potentially preventable healthcare utilization and spending among medicare patients. J Gen Intern Med. 2022. doi:10.1007/s11606-021-07334-y
   Web of Science ®Google Scholar
• Piña IL, Di Palo KE, Brown MT, et al. Medication adherence: importance, issues and policy: a policy statement from the American Heart Association. Prog Cardiovasc Dis. 2021;64:111–120. doi:10.1016/j.pcad.2020.08.003
   PubMed Web of Science ®Google Scholar
• Corrao G, Scotti L, Zambon A, et al. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. Atherosclerosis. 2011;217(2):479–485. doi:10.1016/j.atherosclerosis.2011.04.014
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Calabria S, Rossi E, Martini N. Use of lipid lowering drugs in patients at very high risk of cardiovascular events: an analysis on nearly 3,000,000 Italian subjects of the ARNO Observatory. Int J Cardiol. 2017;246:62–67. doi:10.1016/j.ijcard.2017.02.108
   PubMed Web of Science ®Google Scholar
• Radley-Gardner O, Beale H, Zimmermann R, editors. Fundamental Texts on European Private Law. Hart Publishing;2016. Available from http://www.bloomsburycollections.com/book/fundamental-texts-on-european-private-law-1.
   Google Scholar
• Agenzia Italiana del Farmaco (AIFA). Guideline for the classification and conduction of the observational studies on medicines; 2010. Available from: https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/CIRCULARS/Circular%2031st%20May%202010.pdf. Accessed February 14, 2022.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(Supplement 8Suppl 3):S11–21. doi:10.1097/MLR.0b013e31829b1d2a
   PubMed Web of Science ®Google Scholar
• Pharmacy Quality Alliance. Adherence Measures. Available from: https://www.pqaalliance.org/adherence-measures. Accessed February 14, 2022.
   Google Scholar
• Yang Q, Chang A, Ritchey MD, Loustalot F. Antihypertensive medication adherence and risk of cardiovascular disease among older adults: a population-based cohort study. J Am Heart Assoc. 2017;6(6):e006056. doi:10.1161/JAHA.117.006056
   PubMed Web of Science ®Google Scholar
• Wong MCS, Tam WWS, Cheung CSK, et al. Drug adherence and the incidence of coronary heart disease- and stroke-specific mortality among 218,047 patients newly prescribed an antihypertensive medication: a five-year cohort study. Int J Cardiol. 2013;168(2):928–933. doi:10.1016/j.ijcard.2012.10.048
   PubMed Web of Science ®Google Scholar
• Nishimura S, Kumamaru H, Shoji S, Sawano M, Kohsaka S, Miyata H. Adherence to antihypertensive medication and its predictors among non-elderly adults in Japan. Hypertens Res. 2020;43(7):705–714. doi:10.1038/s41440-020-0440-2
   PubMed Web of Science ®Google Scholar
• Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10(18):2973–2985. doi:10.1517/14656560903376186
   PubMed Web of Science ®Google Scholar
• Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol. 2016;225:184–196. doi:10.1016/j.ijcard.2016.09.075
   PubMed Web of Science ®Google Scholar
• Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther. 2007;21(4):311–316. doi:10.1007/s10557-007-6040-4
   PubMed Web of Science ®Google Scholar
• Dragomir A, Côté R, White M, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health. 2010;13(1):87–94. doi:10.1111/j.1524-4733.2009.00583.x
   PubMed Web of Science ®Google Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–530. doi:10.1097/01.mlr.0000163641.86870.af
   PubMed Web of Science ®Google Scholar
• Armstrong SO, Little RA. Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States. Patient Prefer Adherence. 2019;13:1375–1389. doi:10.2147/PPA.S213258
   PubMed Web of Science ®Google Scholar
• Hero C, Karlsson SA, Franzén S, et al. Impact of socioeconomic factors and gender on refill adherence and persistence to lipid-lowering therapy in type 1 diabetes. Diabetes Ther. 2021;12(9):2371–2386. doi:10.1007/s13300-021-01115-w
   PubMed Web of Science ®Google Scholar